Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA.
Stradling JR., Craig SE., Kohler M., Nicoll D., Ayers L., Nunn AJ., Bratton DJ.
UNLABELLED: The Multi-centre Obstructive Sleep Apnoea Interventional Cardiovascular (MOSAIC) trial compared 6 months of CPAP therapy, versus no CPAP, in 391 patients with minimally symptomatic obstructive sleep apnoea (OSA). We now report some exploratory outcomes, markers of systemic inflammation (interleukin 6 (IL-6), IL-10, C reactive protein, tumour necrosis factor). We found no consistent changes (all p values >0.13). TRIAL REGISTRATION NUMBER: ISRCTN 34164388.